MJM MedTalks Season 2
Podcasts

MJM MedTalks (S02E03): Beyond the Hype - GLP-1 Agonists Redefining Glycemic Control

Susan Joanne Wang, MDCM, MSc
Faculty of Medicine and Health Sciences, McGill University
Vanessa Tardio, MD, FRCPC, BSc Nutrition
Department of Medicine, Divison of Endocrinology and Metabolism, MUHC; Department of Medicine, Faculty of Medicine and Health Sciences, McGill University
Michael Tsoukas, MD
Department of Medicine, Division of Endocrinology and Metabolism, MUHC; Department of Medicine, Faculty of Medicine and Health Sciences, McGill University
Katherine Lan, BScH
Faculty of Medicine and Health Sciences, McGill University
Vanessa Ross
Faculty of Medicine and Health Sciences, McGill University
Samy Amghar
Faculty of Medicine and Health Sciences, McGill University
Jan Pack, MSc, BSc
RIKEN Institute; McGill University
Masha (Maryia) Samuel, BSc
Faculty of Medicine and Health Sciences, McGill University
Renée-Claude Bider, BSc
Medical Physics Unit, McGill University
Khiran Arumugam, MSc, BSc
Faculty of Medicine and Health Sciences, McGill University
Predrag Jovanovic, BSc
Faculty of Medicine and Health Sciences, McGill University
Meryem K. Talbo, R.D., MSc, BSc
School of Human Nutrition, McGill University
diabetes management

Published 2024-06-10

Keywords

  • Podcast,
  • diabetes mellitus,
  • pharmaceuticals,
  • obesity,
  • glp-1 agonists,
  • career
  • ...More
    Less

How to Cite

1.
Wang SJ, Tardio V, Tsoukas M, Lan K, Ross V, Amghar S, Pack J, Samuel M, Bider R-C, Arumugam K, Jovanovic P, Talbo MK. MJM MedTalks (S02E03): Beyond the Hype - GLP-1 Agonists Redefining Glycemic Control. McGill J Med [Internet]. 2024 Jun. 10 [cited 2025 Oct. 31];. Available from: https://mjm.mcgill.ca/article/view/1133

Abstract

McGill Journal of Medicine (MJM) MedTalks is a Podcast series where members of the medical and health science communities from McGill and beyond are interviewed on topics related to career, research, advocacy and more. The aim of MedTalks is to open a space where experienced professionals and researchers can share information and advice for trainees in healthcare and medical sciences. In this episode, Susan Wang, MJM Podcast Team Co-Lead and first year Internal Medicine Resident at McGill University interviews guest-experts and endocrinologists Dr. Michael Tsoukas, Assistant Professor in the Department of Medicine at McGill University, and Dr. Vanessa Tardio, Assistant Professor in the Department of Medicine and Program Director of the Endocrinology and Metabolism Residency Training Program at McGill University. This conversation covers GLP-1 agonists, what they are, their uses, the media hype, new and exciting research, and some advice for trainees. The show notes include a glossary of terms, links to publications referenced in the episode, and a full transcript of our conversation.

Downloads

Download data is not yet available.

References

  1. Studies:
  2. Borlaug BA, Kitzman DW, Davies MJ, Rasmussen S, Barros E, Butler J, Einfeldt MN, Hovingh GK, Møller DV, Petrie MC, Shah SJ. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nature medicine. 2023 Sep;29(9):2358-65. https://www.nature.com/articles/s41591-023-02526-x
  3. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023 Dec 14;389(24):2221-32. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
  4. McGuire DK, Busui RP, Deanfield J, Inzucchi SE, Mann JF, Marx N, Mulvagh SL, Poulter N, Engelmann MD, Hovingh GK, Ripa MS. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. Diabetes, Obesity and Metabolism. 2023 Jul;25(7):1932-41.https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.15058
  5. Rossing, P., Baeres, F.M., Bakris, G., Bosch-Traberg, H., Gislum, M., Gough, S.C., Idorn, T., Lawson, J., Mahaffey, K.W., Mann, J.F. and Mersebach, H., 2023. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrology Dialysis Transplantation, 38(9), pp.2041-2051. https://academic.oup.com/ndt/article/38/9/2041/6991221?login=false
  6. News articles:
  7. How Kim Kardashian’s mystery weight loss to fit into Marilyn Monroe’s dress has led to a TikTok craze leading to shortages of a vital ‘miracle’ diabetes jab that battles clinical obesity: https://www.dailymail.co.uk/health/article-11447155/How-unfounded-claims-Kim-Kardashians-weight-loss-led-TikTok-craze-diabetes-drug.html
  8. Proposed class action lawsuit filed against Canadian maker of popular weight loss drug Ozempic: https://bc.ctvnews.ca/proposed-class-action-lawsuit-filed-against-canadian-maker-of-popular-weight-loss-drug-ozempic-1.6629391
  9. Guidelines:
  10. Vallis TM, Macklin D, Russell-Mayhew S. Canadian Adult Obesity Clinical Practice Guidelines: Effective Psychological and Behavioural Interventions in Obesity Management. Available from: https://obesitycanada.ca/wp-content/uploads/2021/07/10-Psych-Interventions-2-v7-with-links-1.pdf